50mg 地塞米松磷酸鈉/Dexamethasone Sodium Phosphate
| 參考價(jià) | ￥ 793 |
| 訂貨量 | ≥1 |
- 公司名稱 上海高創(chuàng)化學(xué)科技有限公司
- 品牌 Selleck
- 型號(hào) 50mg
- 產(chǎn)地 美國(guó)
- 廠商性質(zhì) 代理商
- 更新時(shí)間 2017/11/20 13:21:16
- 訪問次數(shù) 390
聯(lián)系我們時(shí)請(qǐng)說明是化工儀器網(wǎng)上看到的信息，謝謝!
| 供貨周期 | 現(xiàn)貨 | 規(guī)格 | 50mg |
|---|---|---|---|
| 貨號(hào) | S4028 | 主要用途 | 科研 |
地塞米松磷酸鈉/Dexamethasone Sodium Phosphate
化學(xué)數(shù)據(jù)
| 分子量 | 516.4 | 穩(wěn)定性 | 3年 -20°C粉狀 |
|---|---|---|---|
| 化學(xué)式 | C22H30FO8P.2Na | -- -- -- | |
| CAS號(hào) | 55203-24-2 | 別名 | N/A |
| Solubility (25°C) * | 體外 | Water | 103 mg/mL (199.45 mM) |
| DMSO | Insoluble | ||
| Ethanol | Insoluble | ||
| 體內(nèi) | Saline | 30 mg/mL | |
| * <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. | |||
| 化學(xué)名 | Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17-dihydroxy-16-methyl-21-(phosphonooxy)-, sodium salt (1:2), (11β,16α)- | ||
制備儲(chǔ)備液
| 濃度溶劑體積(Water)質(zhì)量 | 1 mg | 5 mg | 10 mg |
| 1 mM | 1.9365 mL | 9.6824 mL | 19.3648 mL |
| 5 mM | 0.3873 mL | 1.9365 mL | 3.8730 mL |
| 10 mM | 0.1936 mL | 0.9682 mL | 1.9365 mL |
| 50 mM | 0.0387 mL | 0.1936 mL | 0.3873 mL |
生物活性
| 產(chǎn)品描述 | Dexamethasone Sodium Phosphate是一種白介素受體抑制劑，抑制COX-2。 | |||||
|---|---|---|---|---|---|---|
| 靶點(diǎn) |
| |||||
| 體外研究 | Dexamethasone抑制人關(guān)節(jié)軟骨細(xì)胞中IL-1誘導(dǎo)的COX-2 mRNA表達(dá)。[1]在MC3T3-E1細(xì)胞中，Dexamethasone抑制腫瘤壞死因子α (TNFα) 誘導(dǎo)的環(huán)氧合酶-2，IC50為1 nM。Dexamethasone與糖皮質(zhì)激素受體結(jié)合，隨后與糖皮質(zhì)激素應(yīng)答元件結(jié)合。[2] Dexamethasone (10 μM)誘導(dǎo)大鼠骨髓基質(zhì)細(xì)胞培養(yǎng)物中成骨細(xì)胞的分化，并提高堿性磷酸酶骨鈣素，骨涎蛋白，以及骨鈣素的mRNA表達(dá)。[3] Dexamethasone (5 μM)治療降低人海馬神經(jīng)前體細(xì)胞的分化和SRE驅(qū)使的基因表達(dá)。[5] | |||||
| 體內(nèi)研究 | 在雄性Fischer F344 大鼠體內(nèi)，Dexamethasone (2毫克/千克)降低80% BrdU標(biāo)記的肝細(xì)胞數(shù)量。在雄性Fischer F344 大鼠體內(nèi)，Dexamethasone (2 毫克/千克)預(yù)處理同時(shí)抑制部分肝切除術(shù)后TNF和IL-6的表達(dá)，并顯著降低肝細(xì)胞的增殖反應(yīng)。Dexamethasone也會(huì)嚴(yán)重減少2-乙酰氨基芴/部分肝切除術(shù)(AAF/PH)方案誘導(dǎo)的卵圓細(xì)胞的感應(yīng)和擴(kuò)張，但是對(duì)膽道結(jié)扎刺激的膽道細(xì)胞增殖沒有任何影響。 [4] 在Sprague-Dawley大鼠體內(nèi)，Dexamethasone (100微克/千克)使BrdU(+)海馬祖細(xì)胞顯著減少59.2%。在Sprague-Dawley大鼠體內(nèi)，Dexamethasone (100微克/千克)減少顆粒細(xì)胞層中ERK的活化。[5] | |||||
| 臨床實(shí)驗(yàn) | ||||||
| 特征 | 對(duì)COX-2良好的選擇性。 | |||||
*的實(shí)驗(yàn)操作 (此*來自于公開的文獻(xiàn)所以Selleck并不保證其有效性)
動(dòng)物實(shí)驗(yàn)：[5]
| 動(dòng)物模型 | Sprague-Dawley大鼠 |
|---|---|
| 配制 | 生理鹽水 |
| 劑量 | 100微克/千克 |
| 給藥處理 | 腹腔注射 |
參考
- [1] Blanco FJ, et al. J Rheumatol, 1999, 26(6), 1366-1373.
- [2] Yamamoto K, et al. FEBS Lett, 2000, 465(2-3), 103-106.
- [3] Rickard DJ, et al. Dev Biol, 1994, 161(1), 218-228.
- [4] Nagy P, et al. Hepatology, 1998, 28(2), 423-429.
- [5] Kim JB, et al. Brain Res, 2004, 1027(1-2), 1-10.
- [6] Wu CY, et al. J Immunol. 1998, 161(6), 2723-2730.
客戶使用selleck產(chǎn)品的實(shí)驗(yàn)數(shù)據(jù)
數(shù)據(jù)來源于[Oncogene, 2013, 32, 1316-29]
Dexamethasone and largazole cooperate to suppress invasion and to restore E-cadherin localization to the cell peripher y. ( a) Phase contrast micrographs showing morphological changes in MDA-MB-231 cells induced by E-cadherin expression combined with 100 nM dexamethasone and 10 nM largazole treatments. Insets show the cells at higher magnification. (b ) Fluorescence (E-Cad-GFP) or immunofluorescence microscopy (g -catenin (g-Cat.)) of 231/E-Cad-GFP cells treated for 72 h with vehicle (Control), 100 n M dexamethasone, 10 nM largazole or 100 nM dexamethasone + 10 nM largazole (Dex. + Larg.). (c ) Invasion assays were per formed with the indicated cell lines treated for 72 h with or without 100 nM dexamethasone + 10 nM largazole using modified Boyden chambers impregnated with matrigel. The results are presented as the average number of cells that invaded through the membrane per field s.d. of five randomly chosen fields, and are representative of three independently per formed experiments.
數(shù)據(jù)來源于[Oncogene, 2013, 32, 1316-29]
(d) BT549 cells were treated and analyzed by immunofluorescence microscopy as in Figure b. (e) BT549 cells were treated as described in Figure b and analyzed for invasion as in Figure 3c. (f) Quantitation of junctional E-cadherin staining of the indicated cell lines treated with DMSO vehicle or Dex.+ Larg. as described in Figure b. Results are presented as the mean of analyses of three different fields of cells for each sample±s.d. Statistical significance was assessed using Student’s t -test.
如果需要*保存，請(qǐng)于零下二十度低溫保存。
禁止用于人體及治療！
特定的存儲(chǔ)和包裝每個(gè)產(chǎn)品的信息在產(chǎn)品說明書上都有注明 。大多數(shù)Selleck產(chǎn)品，在*的條件下存儲(chǔ)可穩(wěn)定保存兩年。產(chǎn)品有時(shí)建議的儲(chǔ)存溫度不同，大多數(shù)建議儲(chǔ)存在-20°C ，抑制劑屬于化學(xué)試劑，可在常溫下運(yùn)輸儲(chǔ)存兩周左右。即使如此，我們保證產(chǎn)品的出貨量將保持產(chǎn)品質(zhì)量的條件下，一般都會(huì)放入冰袋。望閣下收到產(chǎn)品后，請(qǐng)按照產(chǎn)品數(shù)據(jù)表建議適當(dāng)存儲(chǔ)。
地塞米松磷酸鈉/Dexamethasone Sodium Phosphate
采購(gòu)中心
化工儀器網(wǎng)